Recent advances in niacin and lipid metabolism

Current Opinion in Lipidology

Volumn 24, Issue 3, 2013, Pages 239-245

  Kamanna, Vaijinath S ^a,b   Ganji, Shobha H ^a,b   Kashyap, Moti L ^a,b  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cardiovascular disease; Lipids; Lipoproteins; Niacin

Indexed keywords

APOLIPOPROTEIN A1; DIACYLGLYCEROL ACYLTRANSFERASE 2; LIPID; LOW DENSITY LIPOPROTEIN; NICOTINIC ACID; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADIPOCYTE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CIRCULATION; DYSLIPIDEMIA; HUMAN; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; DIACYLGLYCEROL O-ACYLTRANSFERASE; GENE EXPRESSION REGULATION; HUMANS; HYPOLIPIDEMIC AGENTS; LIPID METABOLISM; MICE; MITOCHONDRIAL PROTON-TRANSLOCATING ATPASES; NIACIN; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC; TRIGLYCERIDES;

MUS;

EID: 84880136694     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283613a68     Document Type: Review

References (49)

1. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem Biophys 1955; 54:558-559.
2. Meyers CD, Kamanna VS, Kashyap ML. Niacin therapy in atherosclerosis. Curr Opin Lipidol 2004; 15:659-665. (Pubitemid 39612984)
3. Carlson LA. Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 2005; 258:94-114. (Pubitemid 41025967)
4. Ganji SH, Zhang L-H, Kamanna VS, Kashyap ML. Effect of niacin on lipoproteins and atherosclerosis. Future Lipidol 2006; 1:549-557.
5. Morgan JM, Capuzzi DM, Baksh RI. Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003; 91:1432-1436. (Pubitemid 36694719)
6. Zambon A, Hokanson JE, Brown BG, Brunzell JD. Evidence for a new pathophysiological mecahanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Circulation 1999; 99: 1959-1964. (Pubitemid 29183891)
7. Backes JM, Gibson CA. Effect of lipid lowering drug therapy on small-dense low-density lipoprotein. Ann Pharmacother 2005; 39:523-526. (Pubitemid 40270919)
8. McKenney JM, McCormick LS, Schaefer EJ, et al. Effect of niacin and atrovastatin on lipoprotein subclasses in patients with atherogenic dyslipi-demia. Am J Cardiol 2001; 88:270-274. (Pubitemid 32721954)
9. Wahlberg G, Walldius G, Olsson AG, Kirstein P. Effect of nicotinic acid on serum cholesterol concentrations of high density lipoprotein subfractions HDL2 and HDL3 in hyperlipoproteinaemia. J Intern Med 1990; 228:151-157. (Pubitemid 20257282)
10. Shepherd J, Betteridge J, Van Gaal L. European Consensus Panel. Nicotinic acid in the management of dyslipidemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin 2005; 21:665-682. (Pubitemid 40695288)
11. Sakai T, Kamanna VS, Kashyap ML. Niacin but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol, Arterioscler. Thromb Vasc Biol 2001; 21:1783-1789. (Pubitemid 34219783)
12. Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963; 173:719-722.
13. Carlson LA, Oro L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand 1962; 172: 641-645.
14. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptor for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003; 9:352-355. (Pubitemid 36362793)
15. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278:9869-9874. (Pubitemid 36800490)
16. Soga T, Kamohara M, Takasaki J, et al. Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 2003; 303:364-369. (Pubitemid 36338250)
17. Lauring B, Taggart AKP, Tata JR, et al. Niacin lipid efficacy is independent of both niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med 2012; 4:148ra115.
18. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular apo B degradaqtion by inhibiting triacylglycerol synthesis in human hepatoblastoma (Hep G2) cells. Arterioscler Thromb Vasc Biol 1999; 19:1051-1059. (Pubitemid 29177355)
19. Ganji SH, Tavintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45:1835-1845. (Pubitemid 40990875)
20. Hu M, Chu WCW, Yamashita S, et al. Liver fat reduction with niacin is influenced by DGAT-2 polymorphisms in hypertriglyceridemic patients. J Lipid Res 2012;53:802-809.
21. Grundy SM, Mok HYI, Zech L, et al. Influence of nicotinic acid on metabolism of cholesterol and triglycerides in man. J Lipid Res 1981; 22:24-36. (Pubitemid 11144704)
22. Martinez LO, Jacquet S, Esteve JP, et al. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003; 421:75-79. (Pubitemid 36077087)
23. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implications for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997; 17:2020-2028. (Pubitemid 28057103)
24. Zhang LH, Kamanna VS, Zhang MC, et al. Niacin inhibits surface expression of ATP synthase beta chain in HepG2 cells. Implications for rasing HDL. J Lipid Res 2008; 49:1195-1201.
25. Kamanna VS, Kashyap ML. Mechanism ofaction of niacin. Am J Cardiol 2008; 101:20B-26B.
26. Blum CB, Levy RI, Eisenberg S, et al. High density lipoprotein metabolism in man. J Clin Invest 1977; 60:795-807. (Pubitemid 8208471)
27. Shepherd J, Packard CJ, Patsch JR, et al. Effect of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. J Clin Invest 1979; 63:858-867. (Pubitemid 9182535)
28. Lamon-Fava S, Diffenderfer MR, Barrett PH, et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008; 28:1672-1678.
29. Glass CK, Pittman RC, Keller GA, et al. Tissue sites of degradation of apoprotein A-I in the rat. J Biol Chem 1983; 258:7161-7167. (Pubitemid 13059968)
30. Saku K, Mendoza SG, Laver M, et al. High-density lipoprotein apolipoprotein AI and AII turnover in moderate and severe proteinuria. Nephron 1988; 5:112-115.
31. Chau P, Nakamura Y, Fielding CJ, et al. Mechanism of prebeta-HDL formation and activation. Biochemistry 2006; 45:3981-3987.
32. Lee JY, Parks JS. ATP-binding cassette transporter AI and its role in HDL formation. Curr Opin Lipidol 2005; 16:19-25. (Pubitemid 40333362)
33. Rothblat GH, Phillips MC. High-density lipoprotein heterogeneity and function in reverse cholesterol transport. Curr Opin Lipidol 2010; 21: 229-238.
34. Mulya A, Lee JY, Gebre AK, et al. Initial interaction of apoA-I with ABCA1 impacts in vivo metabolic fate of nascent HDL. J Lipid Res 2008; 49:2390-2401.
35. Zhang LH, Kamanna VS, Ganji SH, et al. Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apoli-poprotein A-I in HepG2 cells. J Lipid Res 2012; 53:941-950.
36. Ganji SH, Qin S, Zhang L, et al. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009; 202:68-75.
37. Wu BJ, Yan L, Charlton F, et al. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscl Thromb Vasc Biol 2010; 30:968-975.
38. Holzhauser E, Albrecht C, Zhou Q, et al. Nicotinic acid has antiatherogenic and anti-inflammatory properties on advanced atherosclerotic lesions independent of its lipid-modifying capabilities. J Cardiovasc Pharmacol 2011; 57:447-454.
39. Lukasova M, Malaval C, Gille A, et al. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expression in immune cells. J Clin Invest 2011; 121:1163-1173.
40. Digby JE, Martinez F, Jefferson A, et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscl Thromb Vasc Biol 2012; 32:669-676.
41. Bergt C, Pennathur S, Fu X, et al. The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABAA1-dependent cholesterol transport. Proc Natl Acad Sci U S A 2004; 101:13032-13037. (Pubitemid 39167578)
42. Pennathur S, Bergt C, Shao B, et al. Human atherosclerotic intima and blood of patients with established coronary artery disease contain high density lipoprotein damaged by reactive nitrogen species. J Biol Chem 2004; 279:42977-42983. (Pubitemid 39372190)
43. Zheng L, Nukuna B, Brennan ML, et al. Apolipoprotein A-I is a selective target for myeloperoxidase catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest 2004; 114:529-541. (Pubitemid 39572103)
44. Undurti A, Huang Y, Lupica JA, et al. Modification of HDL by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 2009; 284:30825-30835.
45. Ganji S, Xiong X, Kamanna VS, Kashyap ML. Niacin inhibits myeloperoxidase activity and oxidative degradation of HDL and apo AI in human leukocytic myeloid cell line HL-60: Impact on anti-inflammatory properties of HDL. Atherosclerosis (Supplement) 2009; 10:e1182A.
46. Investigators AIM-HIGH, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:2255-2267.
47. Michos ED, Sibly CT, Baer JT, et al. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH trial with previous surrogate endpoint trials. J Am Coll Cardiol 2012; 59:2058-2064.
48. Guyton JR, Slee AE, Anderson T, et al. Relation of lipoprotein levels to cardiovascular events in the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High triglyceride and Impact on Global Health Outcomes (AIM-HIGH) Trial. Circulation 2012; 126(Suppl 21):abstract 14501.
49. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol 2013; 61:440-446.